<DOC>
	<DOCNO>NCT00236977</DOCNO>
	<brief_summary>To assess safety efficacy two form iron therapy treatment anemia non-dialysis dependent , chronic renal failure patient receive receive erythropoietin .</brief_summary>
	<brief_title>Comparison Safety Efficacy Intravenous Iron Versus Oral Iron Chronic Renal Failure Subjects With Anemia</brief_title>
	<detailed_description>The intent study assess safety efficacy two form iron therapy treatment anemia non-dialysis dependent , chronic renal failure patient receive receive erythropoietin . After extensive enrollment period , patient randomize receive oral iron ( ferrous sulfate , 325mg three time daily ( TID ) 56 day ) IV iron sucrose ( total 1000mg , 500mg X 2 OR 200mg X 5 within two week ) . Erythropoietin schedule remain unchanged 56 day study .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<criteria>Hemoglobin &lt; = 11.5 gm/dL Stable dose receive EPO Renal Anemia IV iron last 6 month Chronic infection , malignancy , major surgery within last month Blood Transfusion last two month Significant blood loss within last 3 month Concomitant sever diseases liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>CKD</keyword>
	<keyword>iron</keyword>
	<keyword>anemia</keyword>
</DOC>